/manager/Index ${session.getAttribute("locale")} 5 Predictive algorithms for adjuvant therapy: transATAC /manager/Repository/uon:12497 Sat 24 Mar 2018 08:15:55 AEDT ]]> Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer /manager/Repository/uon:13280 Sat 24 Mar 2018 08:15:16 AEDT ]]> Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial /manager/Repository/uon:5453 Sat 24 Mar 2018 07:48:12 AEDT ]]> Estrogen receptor expression in 21-gene recurrence score predicts increased late recurrence for estrogen-positive/HER2-negative breast cancer /manager/Repository/uon:22830 interaction = 0.004). Estrogen receptor transcript levels showed inverse prediction across the time windows: HR, 0.88 (0.73–1.07) and 1.19 (0.99–1.43), respectively (Pinteraction = 0.03). Similar time-, module-, and estrogen-dependent relationships were seen for distant recurrence. Conclusions: Patients with tumors with high estrogen receptor transcript levels benefit most from 5 years' endocrine therapy but show increased recurrence rates after 5 years and may benefit from extended therapy. Improved prognostic profiles may be created by considering period of treatment and follow-up time.]]> Sat 24 Mar 2018 07:16:07 AEDT ]]>